Carcinosarcomas: Tumors in transition?

Histology and Histopathology

Volumn 30, Issue 6, 2015, Pages 673-687

  Somarelli, Jason A ^a   Boss, Mary Keara ^b   Epstein, Jonathan I ^c   Armstrong, Andrew J ^a   Garcia Blanco, Mariano A ^a,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

EMT; Epithelial mesenchymal transition; Mesenchymal epithelial transition; MET; Sarcomatoid carcinoma

Indexed keywords

CARCINOSARCOMA; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; PATHOLOGY; PROGNOSIS;

CARCINOSARCOMA; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; PROGNOSIS;

EID: 84931837200     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: 10.14670/HH-30.673     Document Type: Review

References (140)

1. Amant F., de la Rey M., Dorfling C.M., van der Walt L., Dreyer G., Dreyer L., Vergote I., Lindeque B.G. and Van Rensburg E.J. (2002). Pten mutations in uterine sarcomas. Gynecol. Oncol. 85, 165-169.
2. Bansal A., Kumar N. and Sharma S.C. (2013). Sarcomatoid variant of urothelial carcinoma of the urinary bladder. J. Cancer Res. Ther. 9, 571-573.
3. Behnsawy H.M., Miyake H., Harada K. and Fujisawa M. (2013). Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: Significance in clinicopathological outcomes following radical prostatectomy. BJU Int. 111, 30-37.
4. Beuselinck B., Lerut E., Wolter P., Dumez H., Berkers J., Van Poppel H., Joniau S., Oyen R., De Wever L. and Strijbos M. (2014). Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti–vascular endothelial growth factor receptor tyrosine kinase inhibitors: A retrospective analysis. Clin. Genitourin. cancer. Cancer 12, e205-214.
5. Bitterman P., Chun B. and Kurman R.J. (1990). The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am. J. Surg. Pathol. 14, 317-328.
6. Bitting R.L., Schaeffer D., Somarelli J.A., Garcia-Blanco M.A. and Armstrong A.J. (2014). The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev. 33, 441-468.
7. Blaukovitsch M., Halbwedl I., Kothmaier H., Gogg-Kammerer M. and Popper H.H. (2006). Sarcomatoid carcinomas of the lung--are these histogenetically heterogeneous tumors? Virchows Archiv. 449, 455-461.
8. Bowen K.A., Doan H.Q., Zhou B.P., Wang Q., Zhou Y., Rychahou P.G. and Evers B.M. (2009). Pten loss induces epithelial--mesenchymal transition in human colon cancer cells. Anticancer Res. 29, 4439 4449.
9. Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L.A., Knuechel R. and Kirchner T. (2001). Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA 98, 10356-10361.
10. Brown E., Stewart M., Rye T., Al‐Nafussi A., Williams A.R., Bradburn M., Smyth J. and Gabra H. (2004). Carcinosarcoma of the ovary. Cancer 100, 2148-2153.
11. Cangiano T., Liao J., Naitoh J., Dorey F., Figlin R. and Belldegrun A. (1999). Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J. Clin. Oncol. 17, 523-523.
12. Cantrell L.A. and Van Le L. (2009). Carcinosarcoma of the ovary: A review. Obstet. Gynecol. Surv. 64, 673-680.
13. Cantrell L.A., Havrilesky L., Moore D.T., O'Malley D., Liotta M., Secord A.A., Nagel C.I., Cohn D.E., Fader A.N. and Wallace A.H. (2012). A multi-institutional cohort study of adjuvant therapy in stage i–ii uterine carcinosarcoma. Gynecol. Oncol. 127, 22-26.
14. Castilla M.A., Moreno-Bueno G., Romero-Perez L., Van De Vijver K., Biscuola M., Lopez-Garcia M.A., Prat J., Matias-Guiu X., Cano A., Oliva E. and Palacios J. (2011). Micro-rna signature of the epithelialmesenchymal transition in endometrial carcinosarcoma. J. Pathol. 223, 72-80.
15. Cheville J.C., Lohse C.M., Zincke H., Weaver A.L., Leibovich B.C., Frank I. and Blute M.L. (2004). Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome. Am. J. Surg. Pathol. 28, 435-441.
16. Chiyoda T., Tsuda H., Tanaka H., Kataoka F., Nomura H., Nishimura S., Takano M., Susumu N., Saya H. and Aoki D. (2012). Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma? Genes Chromosomes Cancer 51, 229-239.
17. Cicin I., Saip P., Eralp Y., Selam M., Topuz S., Ozluk Y., Aydin Y. and Topuz E. (2008). Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol. Oncol. 108, 136-140.
18. Costa M.J., Vogelsan J. and Young L.J. (1994). P53 gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): A clinicopathologic study of 74 cases. Mod. Pathol. 7, 619-627.
19. de Peralta-Venturina M., Moch H., Amin M., Tamboli P., Hailemariam S., Mihatsch M., Javidan J., Stricker H., Ro J.Y. and Amin M.B. (2001). Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases. Am. J. Surg. Pathol. 25, 275-284.
20. del Carmen M.G., Birrer M. and Schorge J.O. (2012). Carcinosarcoma of the ovary: A review of the literature. Gynecol. Oncol. 125, 271-277.
21. Delahunt B., Eble J.N., Nacey J.N. and Grebe S.K. (1999). Sarcomatoid carcinoma of the prostate: Progression from adenocarcinoma is associated with p53 over-expression. Anticancer Res. 19, 4279-4283.
22. DeLong W., Grignon D., Eberwein P., Shum D. and Wyatt J. (1993). Sarcomatoid renal cell carcinoma. An immunohistochemical study of 18 cases. Arch. Pathol. Lab. Med. 117, 636-640.
23. Diaz-Martin J., Diaz-Lopez A., Moreno-Bueno G., Castilla M.A., Rosa Rosa J.M., Cano A. and Palacios J. (2014). A core microrna signature associated with inducers of the epithelial-to-mesenchymal transition. J. Pathol. 232, 319-329.
24. Dinh T.V., Slavin R.E., Bhagavan B.S., Hannigan E.V., Tiamson E.M. and Yandell R.B. (1989). Mixed mullerian tumors of the uterus: A clinicopathologic study. Obstet. Gynecol.74, 388-392.
25. Dittus C., Fountzilas M., Saha D. and Magee D. (2014). A rare case of ovarian carcinosarcoma with neuroendocrine diferentiation. J. Community Support Oncol. 12, 71-4.
26. Dumont N., Wilson M.B., Crawford Y.G., Reynolds P.A., Sigaroudinia M. and Tl sty T.D. (2008). Sustai ned i nducti on of epi thel i al to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc. Natl. Acad. Sci. USA 105, 14867-14872.
27. Dundore P.A., Cheville J.C., Nascimento A.G., Farrow G.M. and Bostwick D.G. (1995). Carcinosarcoma of the prostate. Report of 21 cases. Cancer 76, 1035-1042.
28. Dyke J.M., Crook M.L., Pl atten M. and Stewart C.J. (2014). Extravascul ar mi gratory metastasi s i n gynaecol ogi cal carcinosarcoma. Histopathology 65, 363-370.
29. El Harroudi T., Ech-Charif S., Amrani M. and Jalil A. (2010). Primary carcinosarcoma of the skin. J.Hand Microsurg. 2, 79-81.
30. El-Nashar S.A. and Mariani A. (2011). Uterine carcinosarcoma. Clin. Obstet. Gynecol. 54, 292-304.
31. Engelmann D. and Putzer B.M. (2014). Emerging from the shade of p53 mutants: N-terminally truncated variants of the p53 family in emt signaling and cancer progression. Science Signal. 7, re9.
32. Fang Y., Wei J., Cao J., Zhao H., Liao B., Qiu S., Wang D., Luo J. and Chen W. (2013). Protein expression of zeb2 in renal cell carcinoma and its prognostic significance in patient survival. PLoS One 8, e62558.
33. Fukawa T., Numata K., Yamanaka M., Miyamoto T., Kurokawa Y., Kanayama H.O., Kagawa S., Utsunomiya M. and Hirokawa M. (2003). Prostatic carcinosarcoma: A case report and review of literature. Int. J. Urol. 10, 108-113.
34. Garg G., Yee C., Schwartz K., Mutch D.G., Morris R.T. and Powell M.A. (2014). Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: A population-based analysis. Gynecol. Oncol. 133, 242-249.
35. Gasparotto D., Polesel J., Marzotto A., Colladel R., Piccinin S., Modena P., Grizzo A., Sulfaro S., Serraino D., Barzan L., Doglioni C. and Maestro R. (2011). Overexpression of twist2 correlates with poor prognosis in head and neck squamous cell carcinomas. Oncotarget 2, 1165-1175.
36. Gogas J., Kouskos E., Markopoulos C., Mantas D., Antonopoulou Z., Kontzogl ou K., Stamoul i s J. and Kyri akou, V. (2003). Carcinosarcoma of the breast: report of two cases. Eur. J. Gynaecol. Oncol. 24, 93-95.
37. Golshayan A.R., George S., Heng D.Y., Elson P., Wood L.S., Mekhail T.M., Garcia J.A., Aydin H., Zhou M. and Bukowski R.M. (2009). Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy. J. Clin. Oncol. 27, 235-241.
38. Gonzalez Bosquet J., Terstriep S.A., Cliby W.A., Brown-Jones M., Kaur J.S., Podratz K.C. and Keeney G.L. (2010). The impact of multimodal therapy on survival for uterine carcinosarcomas. Gynecol. Oncol. 116, 419-423.
39. Greer B.E., Koh W.-J., Abu-Rustum N., Bookman M.A., Bristow R.E., Campos S.M., Cho K.R., Copeland L., Crispens M.A. and Eifel P.J. (2009). Uterine neoplasms. J. Ntl. Comprehensive Cancer Network 7, 498-531.
40. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y. and Goodall G.J. (2008). The mir 200 family and mir-205 regulate epithelial to mesenchymal transition by targeting zeb1 and sip1. Nat. Cell Biol. 10, 593-601.
41. Growdon W.B., Roussel B.N., Scialabba V.L., Foster R., Dias-Santagata D., Iafrate A.J., Ellisen L.W., Tambouret R.H., Rueda B.R. and Borger D.R. (2011). Tissue-specific signatures of activating pik3ca and ras mutations in carcinosarcomas of gynecologic origin. Gyneco. Oncol. 121, 212-217.
42. Gu M.J. and Choi J.H. (2014). Epithelial-mesenchymal transition phenotypes are associated with patient survival in intrahepatic cholangiocarcinoma. J. Clin. Pathol. 67, 229-234.
43. Haddad J.R. and Reyes E.C. (1970). Carcinosarcoma of the prostate with metastasis of both elements: Case report. J. Urol. 103, 80-83.
44. Hansel D.E. and Epstein J.I. (2006). Sarcomatoid carcinoma of the prostate: A study of 42 cases. Am. J. Surg. Pathol. 30, 1316-1321.
45. Hansel D.E., Herawi M., Montgomery E. and Epstein J.I. (2007). Spindle cell lesions of the adult prostate. Mod. Pathol. 20, 148-158.
46. Harada K., Miyake H., Kusuda Y. and Fujisawa M. (2012). Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: Impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int. 110, E1131-1137.
47. Haraguchi S., Fukuda Y., Sugisaki Y. and Yamanaka N. (1999). Pul monary carci nosarcoma: Immunohi stochemi cal and ultrastructural studies. Pathol. Int. 49, 903-908.
48. Harris M.A., Delap L., Sengupta P., Wilkinson P.M., Welch R., Swindell R., Shanks J.H., Wilson G., Slade R.J. and Reynolds K. (2003). Carcinosarcoma of the ovary. Br. J. Cancer 88, 654-657.
49. Hasan M.R., Sharma R., Saraya A., Chattopadhyay T.K., DattaGupta S., Walfish P.G., Chauhan S.S. and Ralhan R. (2013). Slug is a predictor of poor prognosis in esophageal squamous cell carcinoma patients. PLoS One 8, e82846.
50. Homesley H.D., Filiaci V., Markman M., Bitterman P., Eaton L., Kilgore L.C., Monk B.J. and Ueland F.R. (2007). Phase iii trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: A gynecologic oncology group study. J. Clin. Oncol. 25, 526-531.
51. Hong S.H., Hong S.J., Lee Y. and Kang E.Y. (2013). Primary cutaneous carcinosarcoma of the shoulder: case report with literature review. Dermatol. Surg. 39, 338-340.
52. Hoskins P.J., Le N., Ellard S., Lee U., Ann Martin L., Swenerton K.D. and Tinker A.V. (2008). Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The british columbia cancer agency experience. Gynecol. Oncol. 108, 58-62.
53. Jin Z., Ogata S., Tamura G., Katayama Y., Fukase M., Yajima M. and Motoyama T. (2003). Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: A genetic study with special reference to histogenesis. Int. J. Gynecol. Pathol. 22, 368-373.
54. Jones S., Stransky N., McCord C.L., Cerami E., Lagowski J., Kelly D., Angiuoli S.V., Sausen M., Kann L., Shukla M., Makar R., Wood L.D., Diaz L.A. Jr, Lengauer C. and Velculescu V.E. (2014). Genomic anal yses of gynaecologic carci nosarcomas reveal frequent mutations in chromatin remodelling genes. Nat. Communs. 5, 5006.
55. Kahlert C., Lahes S., Radhakrishnan P., Dutta S., Mogler C., Herpel E., Brand K., Steinert G., Schneider M., Mollenhauer M., Reissfelder C., Klupp F., Fritzmann J., Wunder C., Benner A., Kloor M., Huth C., Contin P., Ulrich A., Koch M. and Weitz J. (2011). Overexpression of zeb2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin. Cancer Res. 17, 7654-7663.
56. Kane C.J., Mallin K., Ritchey J., Cooperberg M.R. and Carroll P.R. (2008). Renal cell cancer stage migration. Cancer 113, 78-83.
57. Karihtala P., Auvinen P., Kauppila S., Haapasaari K.M., JukkolaVuorinen A. and Soini Y. (2013). Vimentin, zeb1 and sip1 are upregul ated i n tri pl e-negati ve and basal -l i ke breast cancers: Association with an aggressive tumour phenotype. Breast Cancer Res. Treat. 138, 81-90.
58. Ki rsch D.G. and Kastan M.B. (1998). Tumor-suppressor p53: Implications for tumor development and prognosis. J. Clin. Oncol. 16, 3158-3168.
59. Kiuru M., McDermott G., Coit D.C., Berger M.F. and Busam K.J. (2014). Basal cell carcinosarcoma with ptch1 mutations in both epithelial and sarcomatoid primary tumor components and in the sarcomatoid metastasis. Am. J. Surg. Pathol. 38, 138-142.
60. Koss M.N., Hochholzer L. and Frommelt R.A. (1999). Carcinosarcomas of the lung: a clinicopathologic study of 66 patients. Am. J. Surg. Pathol. 23, 1514-1526.
61. Krastanova L.J. and Addonizio J.C. (1981). Carcinosarcoma of prostate. Urology 18, 85-88.
62. Kunene V., Miscoria M., Pirrie S., Islam M.R., Afshar M. and Porfiri E. (2013). Sarcomatoid renal cell carcinoma: Clinical outcome and survival after treatment with sunitinib. Clin. Genitourin. Cancer 12, 251-255.
63. Lao X.M., Chen D.Y., Zhang Y.Q., Xiang J., Guo R.P., Lin X.J. and Li J.Q. (2007). Primary carcinosarcoma of the liver: clinicopathologic features of 5 cases and a review of the literature. Am. J. Surg. Pathol. 31, 817-826.
64. Larue L. and Bellacosa A. (2005). Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3' kinase/akt pathways. Oncogene 24, 7443-7454.
65. Lauwers G.Y., Schevchuk M., Armenakas N. and Reuter V.E. (1993). Carcinosarcoma of the prostate. Am. J. Surg. Pathol. 17, 342-349.
66. Leath III C.A., Numnum T.M., Kendrick IV J.E., Frederick P.J., Rocconi R.P., Conner M.G. and Straughn Jr J.M. (2009). Patterns of failure for conservatively managed surgical stage i uterine carcinosarcoma: Implications for adjuvant therapy. Int. J.Gynecol. Cancer 19, 888-891.
67. Lee S.J., Choi S.Y., Kim W.J., Ji M., Lee T.G., Son B.R., Yoon S.M., Sung R., Lee E.J., Youn S.J. and Park S.M. (2013). Combined aberrant expression of e-cadherin and s100a4, but not beta-catenin is associated with disease-free survival and overall survival in colorectal cancer patients. Diag. Pathol. 8, 99.
68. Lena A.M., Shalom-Feuerstein R., Rivetti di Val Cervo P., Aberdam D., Knight R.A., Melino G. and Candi E. (2008). Mir-203 represses 'stemness' by repressing deltanp63. Cell Death Differ. 15, 1187-1195.
69. Li H., TenNapel M.J., Ahmed A., Lin L., Bhatia S.K. and Jacobson G. (2014). Uteri ne carci nosarcoma confi ned to the pel vi s: A retrospective review and outcome analysis. J. Radiotherapy (in press).
70. Lim S.C., Kim D.C., Suh C.H., Kee K.H. and Choi S.J. (1998). Malignant mixed müllerian tumor (homologous type) of the adnexa with neuroendocrine differentiation. J. Korean Med. Sci. 13, 207-210.
71. Lopez-Beltran A., Scarpelli M., Montironi R. and Kirkali Z. (2006). 2004 who classification of the renal tumors of the adults. Eur. Urol. 49, 798805.
72. Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasman W.T., Currie J.L., Yordan E. and Brady M.F. (1993). Prognostic factors in early-stage uterine sarcoma: A gynecologic oncology group study. Cancer 71, 1702-1709.
73. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J. and Weinberg R.A. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
74. Mano M.S., Rosa D.D., Azambuja E., Ismael G., Braga S., D’hondt V., Piccart M. and Awada A. (2007). Current management of ovarian carcinosarcoma. Int. J. Gynecol. Cancer 17, 316-324.
75. Manolitsas T.P., Wain G.V., Williams K.E., Freidlander M. and Hacker N.F. (2001). Multimodality therapy for patients with clinical stage i and ii malignant mixed müllerian tumors of the uterus. Cancer 91, 1437-1443.
76. Matsumoto T., Fujii H., Arakawa A., Yamasaki S., Sonoue H., Hattori K., Kaj i yama Y., Hi rose S. and Tsurumaru M. (2004). Loss of heterozygosity analysis shows monoclonal evolution with frequent genetic progression and divergence in esophageal carcinosarcoma. Hum. Pathol. 35, 322-327.
77. McCluggage W. (2002a). Uterine carcinosarcomas (malignant mixed mullerian tumors) are metaplastic carcinomas. Int. J. Gynecol. Cancer 12, 687-690.
78. McCluggage W.G. (2002b). Malignant biphasic uterine tumours: Carcinosarcomas or metaplastic carcinomas? J. Clin. Pathol. 55, 321-325.
79. Meis J.M. and Lawrence W.D. (1990). The immunohistochemical profile of malignant mixed mullerian tumor. Overlap with endometrial adenocarcinoma. Am. J. Clin. Pathol. 94, 1-7.
80. Menon S., Deodhar K., Rekhi B., Dhake R., Gupta S., Ghosh J., Maheshwari A., Mahantshetty U., Shrivastva S., Budukh A., Tongaonkar H.B. and Kerkar R. (2013). Clinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (ommmt) from a tertiary cancer institute: A series of 27 cases. Indian J. Pathol. Microbiol. 56, 365-371.
81. Mian B.M., Bhadkamkar N., Slaton J.W., Pisters P.W., Daliani D., Swanson D.A. and Pisters L.L. (2002). Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J. Urol. 167, 65-70.
82. Millis J.M., Chang B., Zinner M.J. and Barsky S.H. (1994). Malignant mixed tumor (carcinosarcoma) of the pancreas: A case report supporting organ-induced differentiation of malignancy. Surgery 115, 132-137.
83. Molina A.M., Tickoo S.K., Ishill N., Trinos M.J., Schwartz L.H., Patil S., Feldman D.R., Reuter V.E., Russo P. and Motzer R.J. (2011). Sarcomatoid-variant renal cell carcinoma treatment outcome and survival in advanced disease. Am. J. Cllin. Oncol. 34, 454.
84. Morley S., Hager M.H., Pollan S.G., Knudsen B., Di Vizio D. and Freeman M.R. (2014). Trading in your spindles for blebs: The amoeboid tumor cell phenotype in prostate cancer. Asian J. Androl. 16, 530-535.
85. Mulholland D.J., Kobayashi N., Ruscetti M., Zhi A., Tran L.M., Huang J., Gleave M. and Wu H. (2012). Pten loss and ras/mapk activation cooperate to promote emt and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 72, 1878-1889.
86. Nielsen S.N., Podratz K.C., Scheithauer B.W. and O'Brien P.C. (1989). Clinicopathologic analysis of uterine malignant mixed müllerian tumors. Gynecologic oncology 34, 372-378.
87. Nordal R.R., Kristensen G.B., Stenwig A.E., Nesland J.M., Pettersen E.O. and Trope C.G. (1997). An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol. Oncol. 67, 316-321.
88. Nout R.A., Putter H., Jürgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., van der Steen-Banasik E.M., Mens J.W.M., Slot A., Kroese M.C.S. and van Bunningen B.N. (2009). Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: First results of the randomized portec-2 trial. J. Clin. Oncol. 27, 3547-3556.
89. Oda H., Nakatsuru Y. and Ishikawa T. (1995). Mutations of the p53 gene and p53 protei n overexpressi on are associ ated wi th sarcomatoid transformation in renal cell carcinomas. Cancer Res. 55, 658-662.
90. Omura G., Major F., Blessing J., Sedlacek T., Thigpen J., Creasman W. and Zaino R. (1983). A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52, 626-632.
91. Paniz Mondolfi A.E., Jour G., Johnson M., Reidy J., Cason R.C., Barkoh B.A., Benaim G., Singh R. and Luthra R. (2013). Primary cutaneous carcinosarcoma: Insights into its clonal origin and mutational pattern expression analysis through next-generation sequencing. Hum. Patho.l 44, 2853-2860.
92. Piura B., Rabinovich A., Apel-Sarid L. and Shaco-Levy R. (2009). Carcinosarcoma of the fallopian tube with metastasis of its epithelial component to the ovary, appendix and omentum. J. Obstet. Gynaecol. 29, 566-567.
93. Randjelovic T., Filipovic B., Babic D., Cemerikic V. and Filipovic B. (2007). Carcinosarcoma of the stomach: a case report and review of the literature. World J. Gastroenterol. 13, 5533-5536.
94. Rauh-Hain J.A., Growdon W.B., Rodriguez N., Goodman A., Boruta II D.M., Schorge J.O., Horowitz N.S. and del Carmen M.G. (2011). Carcinosarcoma of the ovary: A case–control study. Gynecol. Oncol. 121, 477-481.
95. Reed N., Mangioni C., Malmström H., Scarfone G., Poveda A., Pecorelli S., Tateo S., Franchi M., Jobsen J. and Coens C. (2008). Phase III randomi sed study to eval uate the rol e of adj uvant pel vi c radiotherapy in the treatment of uterine sarcomas stages I and II: An european organisation for research and treatment of cancer gynaecological cancer group study (protocol 55874). Eur. J. Cancer 44, 808-818.
96. Reka A.K., Chen G., Jones R.C., Amunugama R., Kim S., Karnovsky A., Standiford T.J., Beer D.G., Omenn G.S. and Keshamouni V.G. (2014). Epithelial-mesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients. Carcinogenesis 35, 1292-1300.
97. Rucci N. and Teti A. (2010). Osteomimicry: How tumor cells try to deceive the bone. Front. Biosci. 2, 907-915.
98. Rutledge T.L., Gold M.A., McMeekin D.S., Huh W.K., Powell M.A., Lewin S.N., Mutch D.G., Johnson G.A., Walker J.L. and Mannel R.S. (2006). Carcinosarcoma of the ovary-a case series. Gynecol. Oncol. 100, 128-132.
99. Sak S.D., Orhan D., Yaman O., Tulunay O. and Ozdiler E. (1997). Carcinosarcoma of the prostate. A case report and a possible evidence on the role of hormonal therapy. Urol. Int. 59, 50-52.
100. Sakakura N., Uchida T., Kitamura Y. and Suyama M. (2014). Pulmonary carci nosarcoma successful l y resected usi ng the ri b-cross thoracotomy approach: report of a case. Surg. Today 44, 175-179.
101. Sarrio D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno Bueno G. and Palacios J. (2008). Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68, 989-997.
102. Schaefer I.M., Schweyer S. and Kuhlgatz J. (2012). Chromosomal imbalances in primary hepatic carcinosarcoma. Hum. Pathol.43, 1328-1333.
103. Sheridan C., Kishimoto H., Fuchs R.K., Mehrotra S., Bhat-Nakshatri P., Turner C.H., Goulet R. Jr, Badve S. and Nakshatri H. (2006). Cd44+/cd24- breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res. 8, R59.
104. Shuch B., Said J., La Rochelle J.C., Zhou Y., Li G., Klatte T., Kabbinaavar F.F., Pantuck A.J. and Belldegrun A.S. (2009). Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology-is up-front resection indicated and, if not, is it avoidable? J. Urol. 182, 2164-2171.
105. Shuch B., Bratslavsky G., Linehan W.M. and Srinivasan R. (2012). Sarcomatoid renal cell carcinoma: A comprehensive review of the biology and current treatment strategies. Oncologist 17, 46-54.
106. Siegel R., Naishadham D. and Jemal A. (2013). Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30.
107. Silasi D.A., Illuzzi J.L., Kelly M.G., Rutherford T.J., Mor G., Azodi M. and Schwartz P.E. (2008). Carcinosarcoma of the ovary. Int. J. Gynecol. Cancer 18, 22-29.
108. Silverberg S.G., Major F.J., Blessing J.A., Fetter B., Askin F.B., Liao S. Y. and Mi l l er A. (1990). Carci nosarcoma (mal i gnant mi xed mesodermal tumor) of the uterus: A gynecologic oncology group pathologic study of 203 cases. Int. J. Gynecol. Pathol. 9, 1-19.
109. Staffieri C., Marioni G., Ferraro S.M., Marino F. and Staffieri A. (2007). Carcinosarcoma de novo of the parotid gland. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 104, e35-40.
110. Sood A.K., Sorosky J.I., Gelder M.S., Buller R.E., Anderson B., Wilkinson E.J., Benda J.A. and Morgan L.S. (1998). Primary ovarian sarcoma. Cancer 82, 1731-1737.
111. Sutton G., Brunetto V.L., Kilgore L., Soper J.T., McGehee R., Olt G., Lentz S.S., Sorosky J. and Hsiu J.-G. (2000). A phase iii trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A gynecologic oncology group study. Gynecol. Oncol. 79, 147-153.
112. Takeyoshi I., Yoshida M., Ohwada S., Yamada T., Yanagisawa A. and Morishita Y. (2000). Skin metastasis from the spindle cell component in rectal carcinosarcoma. Hepato-Gastroenterol. 47, 1611-1614.
113. Taki N.H., Laver N., Quinto T. and Wein R.O. (2013). Carcinosarcoma de novo of the parotid gland: case report. Head Neck 35, E161-163.
114. Taube J.H., Malouf G.G., Lu E., Sphyris N., Vijay V., Ramachandran P.P., Ueno K.R., Gaur S., Nicoloso M.S., Rossi S., Herschkowitz J.I., Rosen J.M., Issa J.P., Calin G.A., Chang J.T. and Mani S.A. (2013). Epigenetic silencing of microrna-203 is required for emt and cancer stem cell properties. Sci. Rep. 3, 2687.
115. Tellez C.S., Juri D.E., Do K., Bernauer A.M., Thomas C.L., Damiani L.A., Tessema M., Leng S. and Belinsky S.A. (2011). Emt and stem cell-like properties associated with mir-205 and mir-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 71, 3087-3097.
116. Teramachi K., Kanomata N., Hasebe T., Ishii G., Sugito M. and Ochiai A. (2003). Carcinosarcoma (pure endocrine cell carcinoma with sarcoma components) of the stomach. Pathol. Int. 53, 552-556.
117. Thompson L., Chang B. and Barsky S.H. (1996). Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am. J. Surg. Pathol. 20, 277-285.
118. Thomson S., Petti F., Sujka-Kwok I., Mercado P., Bean J., Monaghan M., Seymour S.L., Argast G.M., Epstein D.M. and Haley J.D. (2011). A systems view of epithelial-mesenchymal transition signaling states. Clin. Exp. Metast. 28, 137-155.
119. Tian W. and Xu D. (2012). Diagnosis and Management of multiple carcinosarcoma of the breast in a young Chinese patient. Breast Care (Basel). 7, 147-149.
120. Tian W., Wang G., Yang J., Pan Y. and Ma Y. (2013). Prognostic role of e-cadherin and vimentin expression in various subtypes of soft tissue leiomyosarcomas. Med. Oncol. 30, 401.
121. Tickoo S.K., Alden D., Olgac S., Fine S.W., Russo P., Kondagunta G.V., Motzer R.J. and Reuter V.E. (2007). Immunohi stochemi cal expression of hypoxia inducible factor-1α and its downstream molecules in sarcomatoid renal cell carcinoma. J. Urol. 177, 1258-1263.
122. Toiyama Y., Yasuda H., Saigusa S., Tanaka K., Inoue Y., Goel A. and Kusunoki M. (2013). Increased expression of slug and vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis 34, 2548-2557.
123. Tokudome N., Sakamoto G., Sakai T., Sarumaru S., Okuyama N., Hori F., Horii R., Akiyama F., Tanabe M., Saito K., Takahashi K. and Kasumi F. (2005). A case of carcinosarcoma of the breast. Breast Cancer 12, 149-153.
124. Tran T.A., Mul l er S., Chaudahri P.J. and Carl son J.A. (2005). Cutaneous carcinosarcoma: adnexal vs. epidermal types define high- and low-risk tumors. Results of a meta-analysis. J. Cutan. Pathol. 32, 2-11.
125. Tsai J.H., Donaher J.L., Murphy D.A., Chau S. and Yang J. (2012). Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725-736.
126. Vega S., Morales A.V., Ocana O.H., Valdes F., Fabregat I. and Nieto M.A. (2004). Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 18, 1131-1143.
127. Wang J., Wang F.W., Lagrange C.A., Hemstreet Iii G.P. and Kessinger A. (2010). Cl i ni cal features of sarcomatoi d carci noma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma 2010.
128. Wang Q.B., Cui B.K., Weng J.M., Wu Q.L., Qiu J.L. and Lin X.J. (2012). Cl i ni copathol ogi cal characteri sti cs and outcome of pri mary sarcomatoid carcinoma and carci nosarcoma of the liver. J. Gastrointest. Surg. 16, 1715-1726.
129. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., Waldvogel B., Vannier C., Darling D., zur Hausen A., Brunton V.G., Morton J., Sansom O., Schuler J., Stemmler M.P., Herzberger C., Hopt U., Keck T., Brabletz S. and Brabletz T. (2009). The emtactivator zeb1 promotes tumorigenicity by repressing stemness inhibiting micrornas. Nat. Cell Biol. 11, 1487-1495.
130. Wolfson A.H., Brady M.F., Rocereto T., Mannel R.S., Lee Y.-C., Futoran R.J., Cohn D.E. and Ioffe O.B. (2007). A gynecologic oncology group randomized phase iii trial of whole abdominal irradiation (wai) vs. Cisplatin-ifosfamide and mesna (cim) as post-surgical therapy in stage i–iv carcinosarcoma (cs) of the uterus. Gynecol. Oncol. 107, 177-185.
131. Wu Y., Zhang X. and Zehner Z.E. (2003). C-jun and the dominantnegative mutant, tam67, induce vimentin gene expression by interacting with the activator sp1. Oncogene 22, 8891-8901.
132. Yamada S.D., Burger R.A., Brewster W.R., Anton D., Kohler M.F. and Monk B.J. (2000). Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 88, 2782-2786.
133. Yamada S., Fuchs B.C., Fujii T., Shimoyama Y., Sugimoto H., Nomoto S., Takeda S., Tanabe K.K., Kodera Y. and Nakao A. (2013). Epi thel i al -to-mesenchymal transi ti on predi cts prognosi s of pancreatic cancer. Surgery 154, 946-954.
134. Yamashita N., Tokunaga E., Kitao H., Hisamatsu Y., Taketani K., Akiyoshi S., Okada S., Aishima S., Morita M. and Maehara Y. (2013). Vimentin as a poor prognostic factor for triple-negative breast cancer. J. Cancer Res. Clin. Oncol.139, 739-746.
135. Yang J., Du X., Wang G., Sun Y., Chen K., Zhu X., Lazar A.J., Hunt K.K., Pollock R.E. and Zhang W. (2014). Mesenchymal to epithelial transition in sarcomas. Eur. J. Cancer 50, 593-601.
136. Yi R., Poy M.N., Stoffel M. and Fuchs E. (2008). A skin microrna promotes differentiation by repressing 'stemness'. Nature 452, 225-229.
137. Yin K., Liao Q., He H. and Zhong D. (2012). Prognostic value of twist and e-cadherin in patients with osteosarcoma. Med. Oncol. 29, 3449-3455.
138. Zhang S., Zhang D. and Sun B. (2007). Vasculogenic mimicry: Current status and future prospects. Cancer lett. 254, 157-164.
139. Zhou W., Lv R., Qi W., Wu D., Xu Y., Liu W., Mou Y. and Wang L. (2014). Snail contributes to the maintenance of stem cell-like phenotype cells in human pancreatic cancer. PLoS One 9, e87409.
140. Zhuang Z., Lininger R.A., Man Y.G., Albuquerque A., Merino M.J. and Tavassoli F.A. (1997). Identical clonality of both components of mammary carcinosarcoma with differential loss of heterozygosity. Mod. Pathol. 10, 354-362.